Mouse Anti-Human CD83 Molecule Monoclonal Antibody

• Cat.No.: CAB11504MH
• Product Overview: Mouse Monoclonal Antibody to Human CD83 Molecule

Specification

• Antigen Description: CD83 antigen, also known as B-cell activation protein, Cell surface protein HB15 and CD83, is a single-pass type I membrane protein which contains one Ig-like V-type (immunoglobulin-like) domain. CD83 is a a conserved member of the immunoglobulin superfamily. CD83 is expressed by activated lymphocytes, Langerhans cells and interdigitating reticulum cells. CD83 is a fascinating cell surface molecule with a unique pattern of expression that has multiple confirmed functions in regulating immune system development and function. CD83 represents an intriguing target for immunotherapy due to its preferential expression on mature dendritic cells (DCs), the most efficient of antigen presenting cells. On the protein level, two different isoforms of CD83 exist: a membrane-bound and a soluble form. The isoforms are generated by different subsets of cells, including DCs, T-cells and B-cells, and also differ in their biological function. While the membrane-bound CD83 is of immune stimulatory capacity, activates T-cells and is important for the generation of thymocytes, the soluble CD83 has the opposite effect and has an immune inhibitory capacity. Due to its immune inhibitory function. CD83 may play a significant role in antigen presentation or the cellular interactions that follow lymphocyte activation. CD83 has great potential for treatment of autoimmune diseases, for organ transplantations, and for immunotherapy, just to name a few examples. Moreover, some viruses prevent recognition by the hosts immune system by specifically targeting CD83 surface expression.
• Specificity: Human CD83. No cross-reactivity in ELISA with Mouse CD83; Human cell lysate (293 cell line)
• Immunogen: Recombinant Human CD83 Protein
• Host: Mouse
• Isotype: Mouse IgG2b
• Species: Human
• Clone: 5F 6E5
• Applications: WB
• Dilution: This antibody can be used at 1-2 μg/mL with the appropriate secondary reagents to detect CD83-His in WB. Using a DAB detection system, the detection limit for CD83-His is approximately 20 ng/lane under non-reducing conditions and 4 ng/lane under reducing conditions.
• Preparation: This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, human cell-derived, recombinant Human CD83. The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
• Format: 0.2 μm filtered solution in PBS with 5% trehalose
• Storage: This antibody can be stored at 2-8 °C for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20 to -70°C. Preservative-Free.Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
• Tag: Non

Gene Information

• Gene Name: CD83 CD83 molecule [ Homo sapiens ]
• Official Symbol: CD83
• Synonyms: CD83; CD83 molecule; CD83 antigen (activated B lymphocytes, immunoglobulin superfamily) ,CD83 molecule; CD83 antigen; BL11; HB15; hCD83; B-cell activation protein; cell surface protein HB15; cell-surface glycoprotein; CD83 antigen (activated B lymphocytes, immunoglobulin superfamily)
• Gene ID: 9308
• mRNA Refseq: NM_001040280
• Protein Refseq: NP_001035370
• MIM: 604534
• UniProt ID: Q01151
• Chromosome Location: 6p23

Reviews

03/16/2021

The experimental conditions are wide, and the experimental results are accurate and reproducible.

08/24/2020

The resulting strips are clear and bright, which greatly exceeds the expected results.

06/10/2020

CD83 activity is maintained for a very long time and can be maintained for a long time, which is very stable and reliable.

Q&As

Could CD83 be a target for immunotherapy?

Yes, CD83 can be targeted as immunotherapy. Immunotherapy for CD83 has been explored in several clinical trials with some efficacy.

Are there population differences in CD83 treatment?

It is unclear whether there is a population difference in CD83 treatment. However, due to factors such as individual differences and genetic polymorphisms, different populations may respond differently to treatment. Therefore, population-specific treatment strategies may need to be individually adapted and optimized.

What are possible aspects of future research on CD83?

Future research on CD83 may involve more in-depth molecular mechanism studies, optimization and improvement of CD83-based immunotherapy strategies, and research on combination with other immunotherapies or drugs.

Is there a relationship between CD83 and other immune checkpoint molecules?

CD83 interacts and regulates with other immune checkpoint molecules. Together, they are involved in the regulation of the immune response.

Is CD83 expression regulated by other molecules?

Yes, CD83 expression is regulated by a variety of molecules, including cytokines, transcription factors, and epigenetic modifications.

What is the therapeutic approach for CD83?

Current treatments for CD83 mainly include immunotherapy and gene therapy. Immunotherapy against CD83 works primarily by modulating the function of dendritic cells and T cells.